Abbott Laboratories $ABT Stock Purchased by Crescent Grove Advisors LLC

Key Points

• Crescent Grove Advisors LLC increased its Abbott Laboratories stake by 377.6% in the third quarter, bringing its holdings to 18,641 shares valued at approximately $1.84 million. Institutional investors and hedge funds collectively own 75.18% of ABT.
• Abbott reported third-quarter revenue of $13.01 billion, up 14.5% year over year, while adjusted EPS was $1.42. However, the company lowered its 2026 sales-growth outlook because of weakness in medical devices, contributing to a decline in the stock.
• Abbott plans to separate its roughly $8.5 billion Nutrition business into an independent publicly traded company by the end of 2027. The tax-free spin-off could unlock value and improve focus, but investors face execution and transition risks.

Crescent Grove Advisors LLC increased its stake in shares of Abbott Laboratories (NYSE:ABT - Free Report) by 377.6% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 18,641 shares of the healthcare product maker's stock after purchasing an additional 14,738 shares during the quarter. Crescent Grove Advisors LLC's holdings in Abbott Laboratories were worth $1,842,000 at the end of the most recent reporting period.

Several other institutional investors also recently modified their holdings of the stock. Parkway Wealth Management Group LLC increased its holdings in Abbott Laboratories by 3.2% in the 3rd quarter. Parkway Wealth Management Group LLC now owns 3,208 shares of the healthcare product maker's stock worth $317,000 after purchasing an additional 98 shares in the last quarter. St. Johns Investment Management Company LLC grew its position in shares of Abbott Laboratories by 1.0% in the 2nd quarter. St. Johns Investment Management Company LLC now owns 9,859 shares of the healthcare product maker's stock valued at $895,000 after buying an additional 101 shares during the last quarter. AA Financial Advisors LLC increased its position in Abbott Laboratories by 1.7% during the 3rd quarter. AA Financial Advisors LLC now owns 6,186 shares of the healthcare product maker's stock valued at $611,000 after purchasing an additional 101 shares during the period. Eagle Bay Advisors LLC boosted its stake in shares of Abbott Laboratories by 1.2% in the 3rd quarter. Eagle Bay Advisors LLC now owns 8,448 shares of the healthcare product maker's stock valued at $835,000 after purchasing an additional 102 shares during the last quarter. Finally, Richards Merrill & Peterson Inc. raised its stake in Abbott Laboratories by 1.1% during the third quarter. Richards Merrill & Peterson Inc. now owns 9,562 shares of the healthcare product maker's stock worth $945,000 after buying an additional 102 shares during the last quarter. 75.18% of the stock is currently owned by institutional investors and hedge funds.

Abbott Laboratories News Summary

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Third-quarter adjusted earnings per share were $1.42, in line with the company’s consensus estimate, while revenue rose 14.5% year over year to $13.01 billion, slightly exceeding expectations. Comparable sales increased 7%, and Abbott reaffirmed its full-year adjusted EPS guidance. Abbott third-quarter results
• Positive Sentiment: Management announced plans to separate its approximately $8.5 billion Nutrition business—including Ensure, Similac, Glucerna, Pedialyte and PediaSure—into an independent, publicly traded company through a tax-free distribution to shareholders, targeted for completion by the end of 2027. Abbott believes the transaction could accelerate growth and expand margins in its remaining businesses. Abbott Nutrition separation announcement
• Positive Sentiment: New product approvals and European authorization for Abbott’s Cologuard Plus colorectal cancer test expand its diagnostics portfolio and could support longer-term growth. Cologuard Plus European approval
• Neutral Sentiment: The spin-off is intended to unlock value by allowing Abbott and the new Nutrition company to pursue separate strategies, but investors must assess execution, tax and transition risks before the separation is completed.
• Negative Sentiment: Abbott lowered its 2026 sales-growth forecast, citing weakness in medical devices. The reduced outlook suggests near-term operating momentum may be softer than previously expected, despite continued strength in areas such as continuous glucose monitoring. Reuters report on Abbott’s outlook
• Negative Sentiment: Some analysts characterized the $1.42 adjusted EPS result as a slight miss against a $1.43 estimate. Combined with the lower sales outlook and uncertainty surrounding the Nutrition separation, that has outweighed the quarter’s revenue growth and caused the stock to decrease.

Analyst Upgrades and Downgrades

ABT has been the topic of several recent analyst reports. Weiss Ratings raised Abbott Laboratories from a "hold (c-)" rating to a "hold (c)" rating in a research note on Friday, September 18th. Robert W. Baird began coverage on Abbott Laboratories in a report on Wednesday, July 1st. They issued an "outperform" rating and a $121.00 price target on the stock. Royal Bank Of Canada reissued an "outperform" rating and issued a $130.00 price target on shares of Abbott Laboratories in a research report on Friday, July 17th. Wolfe Research raised shares of Abbott Laboratories from a "peer perform" rating to an "outperform" rating and set a $130.00 price objective on the stock in a research note on Thursday, August 13th. Finally, Citigroup boosted their target price on shares of Abbott Laboratories from $108.00 to $112.00 and gave the stock a "buy" rating in a research report on Friday, July 17th. Three research analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and four have issued a Hold rating to the stock. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $118.88.

Abbott Laboratories Stock Down 1.8%

Shares of NYSE ABT opened at $100.59 on Thursday. The business's fifty day moving average price is $105.47 and its 200-day moving average price is $98.28. Abbott Laboratories has a one year low of $81.97 and a one year high of $132.02. The stock has a market capitalization of $174.06 billion, a PE ratio of 32.55, a P/E/G ratio of 1.90 and a beta of 0.59. The company has a debt-to-equity ratio of 0.57, a current ratio of 1.38 and a quick ratio of 0.97.

Abbott Laboratories (NYSE:ABT - Get Free Report) last issued its earnings results on Wednesday, October 21st. The healthcare product maker reported $1.42 earnings per share for the quarter, hitting analysts' consensus estimates of $1.42. The firm had revenue of $13.01 billion during the quarter, compared to analyst estimates of $12.99 billion. Abbott Laboratories had a net margin of 11.65% and a return on equity of 17.69%. The company's quarterly revenue was up 14.5% on a year-over-year basis. During the same quarter last year, the business earned $1.30 earnings per share. On average, equities research analysts anticipate that Abbott Laboratories will post 5.53 EPS for the current year.

Abbott Laboratories Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, November 16th. Shareholders of record on Thursday, October 15th will be issued a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a yield of 2.5%. The ex-dividend date of this dividend is Thursday, October 15th. Abbott Laboratories's payout ratio is presently 81.55%.

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company that develops, manufactures and markets a broad range of medical products and services. Founded in 1888 by Wallace C. Abbott, the company is headquartered in Abbott Park, Illinois, and serves patients, healthcare providers and consumers in markets around the world.

Abbott operates across four principal businesses: medical devices, diagnostics, nutrition and established pharmaceutical products. Its offerings include glucose-monitoring systems such as FreeStyle Libre; cardiovascular devices, including stents and structural heart products; laboratory and point-of-care diagnostic systems; and branded generic medicines in areas such as gastroenterology, women's health and cardiometabolic care.

The company's nutrition portfolio includes infant and pediatric products such as Similac and PediaSure, adult nutritional products such as Ensure, and rehydration products such as Pedialyte.

Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.